Iterum Therapeutics PLC (NASDAQ:ITRM) has earned an average recommendation of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $20.75.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research raised Iterum Therapeutics from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a research report on Thursday, March 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $20.00 price target on shares of Iterum Therapeutics in a research report on Monday, March 25th.
Shares of ITRM stock opened at $7.01 on Friday. The firm has a market cap of $102.04 million and a PE ratio of -0.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.61 and a current ratio of 7.61. Iterum Therapeutics has a 12-month low of $4.70 and a 12-month high of $13.00.
Iterum Therapeutics (NASDAQ:ITRM) last issued its quarterly earnings results on Monday, March 25th. The company reported ($1.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.55) by $1.36. The business had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.20 million. On average, analysts predict that Iterum Therapeutics will post -6.4 earnings per share for the current year.
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
Featured Story: How do analysts define an oversold condition?
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.